Evercore ISI Group Boosts Abbott Laboratories Price Target to $145.00
ByAinvest
Saturday, Jul 12, 2025 10:56 am ET1min read
ABT--
The increase in price target comes amidst a strong analyst consensus rating for ABT. According to TipRanks, the consensus rating is a Strong Buy, with a $136.89 average price target, implying a 2.74% upside from current levels [1]. Additionally, Oppenheimer reiterated a Buy rating on the stock with a $140.00 price target [1].
Evercore ISI Group's analyst, Vijay Kumar, who covers the Healthcare sector, maintained a Buy rating on ABT with a price target of $145.00. Kumar has an average return of 1.3% and a 46.99% success rate on recommended stocks [1]. The company has seen a one-year high of $141.23 and a one-year low of $99.71. Currently, Abbott Laboratories has an average volume of 6.59M shares traded daily [1].
The recent corporate insider activity shows a negative sentiment, with 48 insiders selling their shares over the past quarter. Most recently, in May 2025, Sally Blount, a Director at ABT, sold 2,600 shares for a total of $337,116.00 [1].
Abbott Laboratories is expected to meet or exceed Wall Street’s targets for the second quarter, keeping the company on track to achieve its 2025 guidance targets. The company has demonstrated solid operational performance with a P/E ratio of 17.02 and revenue growth of 5% [3].
The company's strong operating momentum and several new growth drivers, such as TriClip in the US market and Volt in Europe, contribute to the optimistic outlook [3]. Abbott Laboratories has maintained dividend payments for 55 consecutive years, showcasing its financial stability [3].
References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/ABT-N/pressreleases/33302590/evercore-isi-reaffirms-their-buy-rating-on-abbott-laboratories-abt/
[3] https://www.investing.com/news/analyst-ratings/abbott-labs-stock-price-target-reiterated-at-145-by-td-cowen-on-strong-outlook-93CH-4132346
EVR--
OPY--
Abbott Laboratories' (ABT) price target has been raised by Evercore ISI Group to $145.00, up from $140.00, reflecting a 3.57% increase. The analyst group maintained its "Outperform" rating for the company. The average target price for ABT is $142.14, with a high estimate of $159.00 and a low estimate of $120.12. The average target implies an upside of 6.31% from the current price.
Abbott Laboratories' (ABT) price target has been raised by Evercore ISI Group to $145.00, up from $140.00, reflecting a 3.57% increase. The analyst group maintained its "Outperform" rating for the company. The average target price for ABT is $142.14, with a high estimate of $159.00 and a low estimate of $120.12. The average target implies an upside of 6.31% from the current price [1].The increase in price target comes amidst a strong analyst consensus rating for ABT. According to TipRanks, the consensus rating is a Strong Buy, with a $136.89 average price target, implying a 2.74% upside from current levels [1]. Additionally, Oppenheimer reiterated a Buy rating on the stock with a $140.00 price target [1].
Evercore ISI Group's analyst, Vijay Kumar, who covers the Healthcare sector, maintained a Buy rating on ABT with a price target of $145.00. Kumar has an average return of 1.3% and a 46.99% success rate on recommended stocks [1]. The company has seen a one-year high of $141.23 and a one-year low of $99.71. Currently, Abbott Laboratories has an average volume of 6.59M shares traded daily [1].
The recent corporate insider activity shows a negative sentiment, with 48 insiders selling their shares over the past quarter. Most recently, in May 2025, Sally Blount, a Director at ABT, sold 2,600 shares for a total of $337,116.00 [1].
Abbott Laboratories is expected to meet or exceed Wall Street’s targets for the second quarter, keeping the company on track to achieve its 2025 guidance targets. The company has demonstrated solid operational performance with a P/E ratio of 17.02 and revenue growth of 5% [3].
The company's strong operating momentum and several new growth drivers, such as TriClip in the US market and Volt in Europe, contribute to the optimistic outlook [3]. Abbott Laboratories has maintained dividend payments for 55 consecutive years, showcasing its financial stability [3].
References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/ABT-N/pressreleases/33302590/evercore-isi-reaffirms-their-buy-rating-on-abbott-laboratories-abt/
[3] https://www.investing.com/news/analyst-ratings/abbott-labs-stock-price-target-reiterated-at-145-by-td-cowen-on-strong-outlook-93CH-4132346
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet